Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration

Published:2022-03-18 Issue:2 Volume:10 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacology Res & Perspec

Author:

Zakaria Nadia¹^ORCID,Guerard Nicolas²,Emanuelli Andres³,Dugel Pravin⁴,Watts Jen⁵,Liew Melissa¹,Gekkieva Margarita²,Hinder Markus⁶^ORCID

Affiliation:

1. Novartis Institutes for BioMedical Research Translational Medicine Cambridge Massachusetts USA

2. Global Drug Development Novartis Pharma AG Basel Switzerland

3. Emanuelli Research and Development Center Arecibo Puerto Rico USA

4. IVERIC bio New York New York USA

5. Novartis Pharmaceuticals Corporation East Hannover New Jersey USA

6. Novartis Institutes for BioMedical Research Translational Medicine Basel Switzerland

Funder

Novartis Pharma

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.897

Reference21 articles.

1. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

2. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

3. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

4. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

5. Ranibizumab for Neovascular Age-Related Macular Degeneration

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Brolucizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis;PeerJ;2024-06-21

2. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy;Genes;2024-01-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3